Biogen partners with TRIMTECH on neurodegenerative disease protein degraders
Biogen has entered a research collaboration with TRIMTECH Therapeutics to develop small molecule protein degraders for neurodegenerative diseases, in a deal potentially worth up to $411 million plus royalties.
The collaboration, option and licence agreement will combine TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology with Biogen’s expertise in neurodegenerative disease drug development.
The companies will work together to discover and develop small molecule protein degraders targeting protein aggregates associated with neurodegenerative conditions.
Under the agreement, TRIMTECH is eligible to receive up to $32 million in upfront and research milestone payments. If Biogen exercises its option, it will receive a global exclusive licence to the degraders developed through the collaboration and take responsibility for subsequent development and commercialisation.
The agreement also includes potential payments bringing the total deal value to up to $411 million, in addition to royalties.
TRIM21 technology targets toxic protein aggregates
TRIMTECH is developing small molecule therapies using its proprietary TRIM21-based targeted protein degradation platform.
The technology is built around TRIM21, an E3 ligase involved in the cellular protein degradation process. The company’s TRIMTAC and TRIMGLUE degrader technologies are designed to selectively target and remove disease-associated proteins.
According to TRIMTECH, its small molecule degraders can access the central nervous system (CNS) and target toxic protein aggregates and oligomers implicated in neurodegenerative diseases.
Protein aggregation is associated with several neurodegenerative conditions, making targeted degradation an area of interest for drug discovery. Approaches that remove disease-associated proteins could offer an alternative to treatments that primarily address symptoms or target individual disease pathways.
TRIMTECH was founded on academic research into TRIM21 and is focused on developing small molecule therapeutics for diseases involving toxic protein accumulation.
Biogen collaboration supports further drug discovery
The agreement gives Biogen the option to obtain global exclusive rights to the degraders generated through the research collaboration.
The financial structure combines upfront and research milestone payments with further potential development and commercialisation milestones. The companies have not disclosed the specific neurodegenerative diseases or protein targets covered by the agreement.
Dr Nicki Thompson, CEO of TRIMTECH Therapeutics, said: “We are excited to enter this strategic collaboration with Biogen, which is a major milestone for TRIMTECH. This is a significant validation of the progress we have made and the potential of our TRIM21-based targeted protein degradation platforms.”
She added: “Combining our expertise with Biogen’s strong legacy and experience in developing treatments for neurodegenerative diseases brings new promise to the potential of delivering more effective therapies for patients.”
The collaboration adds to research into targeted protein degradation as a potential approach to treating neurodegenerative disease, with the companies aiming to advance small molecule candidates capable of targeting disease-associated proteins in the CNS.




